Patents by Inventor Yonghua Gai

Yonghua Gai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIFLUORINATED TRIPEPTIDES AS HCV SERINE PROTEASE INHIBITORS
    Publication number: 20090202486
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: January 22, 2009
    Publication date: August 13, 2009
    Inventors: Yonghua GAI, Yat Sun OR, Zhe WANG
  • HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS
    Publication number: 20090202485
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: January 22, 2009
    Publication date: August 13, 2009
    Inventors: YONGHUA GAI, YAT SUN OR, ZHE WANG
  • FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS
    Publication number: 20090197888
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: December 4, 2008
    Publication date: August 6, 2009
    Inventors: YONGHUA GAI, Yat Sun Or, Zhe Wang
  • TRIAZOLE-CONTAINING MACROCYCLIC HCV SERINE PROTEASE INHIBITORS
    Publication number: 20090191151
    Abstract: The present invention discloses compounds of formula I, II and III or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: December 12, 2008
    Publication date: July 30, 2009
    Inventors: Yonghua GAI, Yat Sun OR, Zhe WANG
  • Processes for the preparation of -(2-aminobenzo[]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182
    Patent number: 7563877
    Abstract: The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivative known as EDP-182 (IX-a).
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: July 21, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoyou Xu, Yonghua Gai, Guoqlang Wang, Yat Sun Or, Zhe Wang
  • MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20090180984
    Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Application
    Filed: December 12, 2008
    Publication date: July 16, 2009
    Inventors: Ying Sun, Yonghua Gai, Yat Sun Or, Zhe Wang
  • QUINOXALINYL DERIVATIVES
    Publication number: 20090180981
    Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Application
    Filed: December 3, 2008
    Publication date: July 16, 2009
    Inventors: Deqiang Niu, Dong Liu, Joel D. Moore, Guoyou Xu, Ying Sun, Yonghua Gai, Datong Tang, Yat Sun Or, Zhe Wang
  • OXIMYL HCV SERINE PROTEASE INHIBITORS
    Publication number: 20090155210
    Abstract: The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: December 4, 2008
    Publication date: June 18, 2009
    Inventors: YONGHUA GAI, Yat Sun Or, Zhe Wang
  • HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR
    Publication number: 20090123423
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: April 24, 2008
    Publication date: May 14, 2009
    Inventors: Yonghua Gai, Yat Sun Or, Zhe Wang
  • Spirocyclic bicyclolides
    Patent number: 7517859
    Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: April 14, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yonghua Gai, Datong Tang, Ying Sun, Zhigang Chen, Yat Sun Or, Zhe Wang
  • ARYLALKOXYL HEPATITIS C VIRUS PROTEASE INHIBITORS
    Publication number: 20090041721
    Abstract: The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.
    Type: Application
    Filed: August 9, 2007
    Publication date: February 12, 2009
    Inventors: Deqiang Niu, Yonghua Gai, Yat Sun Or, Zhe Wang
  • QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS
    Publication number: 20090005387
    Abstract: The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: January 18, 2008
    Publication date: January 1, 2009
    Inventors: Deqiang Niu, Dong Liu, Joel D. Moore, Guoyou Xu, Ying Sun, Yonghua Gai, Datong Tang, Yat Sun Or, Zhe Wang
  • OXIMYL HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS PROTEASE INHIBITOR
    Publication number: 20080274082
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: April 24, 2008
    Publication date: November 6, 2008
    Inventors: Yonghua Gai, Ying Sun, Yat Sun Or, Zhe Wang
  • CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20080267916
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: April 26, 2007
    Publication date: October 30, 2008
    Inventors: Yonghua Gai, Deqiang Niu, Yat Sun Or, Zhe Wang
  • QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS
    Publication number: 20080267918
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: April 24, 2008
    Publication date: October 30, 2008
    Inventors: Yonghua Gai, Yat Sun Or, Zhe Wang
  • POLYMORPHIC FORMS OF 6-11 BICYCLIC KETOLIDE DERIVATIVES
    Publication number: 20080248105
    Abstract: The present invention includes EP-13420 polymorphic crystalline forms: Form I, Form II, Form Ia, and monohydrate and amorphous EP-13420 which posses distinct physical properties. In another embodiment of the present invention, there are provided methods of producing the various polymorphic forms in pure form or in combination with one another. The present invention also provides pharmaceutical compositions and formulations comprising the polymorphic and amorphous forms and methods of treating bacterial infections by administering the pharmaceutical compositions to a subject in need of such treatment.
    Type: Application
    Filed: April 18, 2008
    Publication date: October 9, 2008
    Inventors: Datong Tang, Guoyou Xu, Yonghua Gai, Zhe Wang, Yat Sun Or, Hui-Yin Li
  • 3,6-bicyclolides
    Patent number: 7419962
    Abstract: The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
    Type: Grant
    Filed: December 6, 2005
    Date of Patent: September 2, 2008
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Datong Tang, Ying Sun, Yonghua Gai, Guoyou Xu, Zhe Wang
  • Polymorphic forms of 6-11 bicyclic ketolide derivatives
    Patent number: 7384921
    Abstract: The present invention includes EP-13420 polymorphic crystalline forms: Form I, Form II, Form Ia, and monohydrate and amorphous EP-13420 which posses distinct physical properties. In another embodiment of the present invention, there are provided methods of producing the various polymorphic forms in pure form or in combination with one another. The present invention also provides pharmaceutical compositions and formulations comprising the polymorphic and amorphous forms and methods of treating bacterial infections by administering the pharmaceutical compositions to a subject in need of such treatment.
    Type: Grant
    Filed: February 14, 2005
    Date of Patent: June 10, 2008
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Datong Tang, Guoyou Xu, Yonghua Gai, Zhe Wang, Yat Sun Or, Hui-Yin Li
  • ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS
    Publication number: 20080085894
    Abstract: There is provided a series of novel ?-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid activity.
    Type: Application
    Filed: October 11, 2007
    Publication date: April 10, 2008
    Inventors: Michael Parker, Katharine McElhone, Robert Mate, Joanne Bronson, Yonghua Gai, Carl Bergstrom, Lawrence Marcin, John Macor
  • Acylaminoheteroaryl hepatitis C virus protease inhibitors
    Publication number: 20080039470
    Abstract: The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: August 11, 2006
    Publication date: February 14, 2008
    Inventors: Deqiang Niu, Joel D. Moore, Dong Liu, Yonghua Gai, Zhigang Chen, Yat Sun Or, Zhe Wang